Your browser doesn't support javascript.
loading
Quality of life in adolescents with narcolepsy type 1- a transversal study in a tertiary hospital.
Salazar, Luís; Vieira, Paula Manuel; Cascais, Inês; Figueiroa, Sónia; Rios, Marta.
Afiliação
  • Salazar L; Serviço de Pediatria, Centro Materno-Infantil do Norte Albino Aroso (CMIN), Centro Hospitalar Universitário de Santo António (CHUdSA), Porto, Portugal. Electronic address: luis.salazar@hotmail.com.
  • Vieira PM; Serviço de Pediatria, Centro Materno-Infantil do Norte Albino Aroso (CMIN), Centro Hospitalar Universitário de Santo António (CHUdSA), Porto, Portugal.
  • Cascais I; Serviço de Pediatria, Centro Materno-Infantil do Norte Albino Aroso (CMIN), Centro Hospitalar Universitário de Santo António (CHUdSA), Porto, Portugal.
  • Figueiroa S; Serviço de Neuropediatria, CMIN, CHUdSA, Porto, Portugal.
  • Rios M; Serviço de Pediatria, Centro Materno-Infantil do Norte Albino Aroso (CMIN), Centro Hospitalar Universitário de Santo António (CHUdSA), Porto, Portugal.
Sleep Med ; 113: 215-219, 2024 01.
Article em En | MEDLINE | ID: mdl-38056083
PURPOSE: - Narcolepsy type 1 (NT1) is a rare chronic sleep disorder, usually arising by adolescence that negatively impacts quality of life. It is characterized by excessive daytime sleepiness (EDS), cataplexy, hypnagogic/hypnopompic hallucinations, sleep paralysis and sleep fragmentation. The goals of this work were to characterize NT1 adolescents regarding sleep characteristics, health-related quality of life (HRQoL) and future life perspectives and later to compare this group with a control group of healthy adolescents (HA). METHODS: - Transversal descriptive/analytical study including NT1 patients followed in a sleep center of a tertiary hospital and 23 HA. Data were collected through an online survey, fulfilled by the participants, including four sections: demographics; questionnaire evaluating sleep and EDS; questionnaire evaluating HRQoL; inquiry regarding future perspectives. An extra section for the NT1 group only, comprising questions about the characterization of narcolepsy, was included. RESULTS: 22 NT1 adolescents were included, with a median age of 15.0 years-old. Beyond EDS, all had presented cataplexy - 19 still reported it. Twenty patients took psychostimulants regularly for EDS, while 13 patients took venlafaxine or fluoxetine for cataplexy. Nineteen adolescents took regular naps and 19 maintained psychological appointments. Self-reported sleep quality was similar between groups (p = 0.112). EDS was identified in seven NT1 patients and none in the control group. HRQOL was significantly lower in NT1 patients only for the physical well-being domain (p = 0.001). Regarding future perspectives, results were similar, except for a lower probability of getting a driver's license in NT1 patients, despite no statistical significance (p = 0.104). DISCUSSION: Daytime sleepiness is difficult to control in NT1, despite specialized treatment. HRQoL was similar between groups in all domains except for the physical well-being. Despite good adherence to pharmacological and non-pharmacological treatments (namely psychological therapy) that account for these good results, the physical well-being domain is difficult to manage.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cataplexia / Distúrbios do Sono por Sonolência Excessiva / Narcolepsia Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cataplexia / Distúrbios do Sono por Sonolência Excessiva / Narcolepsia Idioma: En Ano de publicação: 2024 Tipo de documento: Article